Budgeting a Complex Trial
Applied Clinical Trials
Allison Burmeister discussed the average cost increase based on the per patient cost in a clinical trial during her presentation at the ExL Pharma C.R.O.W.N. Event.
"Clinical trials are labor intensive," emphasized Allison Burmeister, Senior Analyst, Clinical Business Operations for Janssen Alzheimer Immunotherapy R&D, during her presentation last month at the ExL Pharma C.R.O.W.N. Event, when presenting her case study on "Mitigating Risks and Variance When Budgeting and Contracting for a Complex Global Clinical Trial."
Burmeister's presentation began with an outline of the average cost increase based on the per patient cost in a clinical trial, from which she gleaned from a July 2011 article on Pharmalot that was based on a Cutting Edge Information survey. Those costs per patient are as follows in 2011: Phase I: $21,883; Phase II: $35,070; Phase IIIa: $47,523; Phase IIIb: $47,095; and Phase IV: $17,042.
That snapshot set the stage for Burmeister's case study, of which she referred to a 210 site, 1,670 subject, four-year long, 14 country, Phase III study. The average study start-up costs were budgeted at $4.4M—and this is even before a trial starts to enroll.
Burmeister urged the audience to consider that no scope or budget detail is too small because the chance for it not to be included could significantly shift the variance of a budget.
For example, screen fail rates. For this particular trial, Burmeister went to the project managers and the sites to ask how many patients they thought wouldn't pass the screen and came up with a 64%. So if a total of 7,200 potential subjects fail the screen, the cost would be $15 million. Said Burmeister, "If that is not factored into the budget, that could be a considerable variance to cost."
Other key factors beyond the screen fail rate that impact the trial include the number of subjects, the enrollment rate over the length of the trial (has to be factored over the number of years), drop-out rate, number of sites, the site activation rate, and the schedule of assessments. The schedule of assessments, again should be extremely detailed so that the number of procedures per patient are truly counted into the budget.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
